REGENXBIO Announces Additional Positive Interim Phase I Trial Update for RGX-314

REGENXBIO Inc.  a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, announced updated results from the ongoing Phase I study of RGX-314 for the treatment of wet age-related macular degeneration.

The results were presented by Jeffrey Heier, M.D., Co-President and Director of Retina Research at Ophthalmic Consultants of Boston, and primary investigator for the trial, at the Retina Subspecialty Day program of the American Academy of Ophthalmology (AAO) 2018 Annual Meeting.

In August 2018, REGENXBIO presented an interim trial update on the first three dose cohorts, as of July 27, 2018, demonstrating that RGX-314 was well-tolerated and showed dose-dependent protein expression levels and dose-dependent reductions in anti-vascular endothelial growth factor (anti-VEGF) injections, along with maintenance of central retinal thickness and vision. Of the subjects treated at the 6 x 10^10 (Cohort 3) genome copies (GC)/eye dose, 50 percent were free of anti-VEGF injections at six months. A summary of these data can be found here.

“Many wet AMD patients require frequent anti-VEGF injections to maintain their vision. The burden of such treatment weighs upon patients, their family and their caregivers. Patients such as these were enrolled in the RGX-314 trial,” said Dr. Heier. “The dose-dependent protein expression in the trial, coupled with the sustained expression at six months in Cohort 3 is encouraging. RGX-314 has the potential to provide optimal long-term visual outcomes with a single treatment.”

Detailed study findings presented by Dr. Heier at AAO 2018 are available here.

Phase I Trial Dose Expansion and Status of Expected Phase II Trial

REGENXBIO recently announced it has completed dosing (six subjects) in the Phase I clinical trial of RGX-314 at the 1.6 x 10^11 GC/eye (Cohort 4) dose. A total of 24 subjects have now been dosed in the trial. REGENXBIO plans to initiate a Phase II clinical trial for RGX-314 in 2019. Final determination of the study design is under way. REGENXBIO expects to provide further information regarding the initial assessments of protein expression levels from Cohort 4, anticipated Phase II clinical trial design and overall plans for the RGX-314 clinical program in early 2019.

“We continue to be encouraged by the RGX-314 interim results and the potential of NAV® gene therapy as a one-time treatment for wet AMD, a leading cause of irreversible blindness and visual impairment in the world,” said Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO. “We extend our thanks to the patients and the investigators who have participated in this trial and contributed to the growing body of evidence to give hope to patients living with wet AMD for a long-lasting solution to their condition.”  

Seven leading retinal surgery centers across the United States are participating in the Phase I clinical trial of RGX-314. This multi-center, open-label, multiple-cohort, dose-escalation clinical trial is designed to assess the safety and tolerability of RGX-314 as a one-time therapy for patients with previously treated wet AMD. For further details on the trial, enrollment criteria and eligibility, visit clinicaltrials.gov/ct2/show/NCT03066258.

About the Phase I Clinical Trial of RGX-314
RGX‑314 is currently being evaluated in a Phase I, multi-center, open-label, multiple-cohort, dose‑escalation study in adult subjects with wet AMD in the United States. The study has enrolled 24 previously treated wet AMD subjects across four cohorts that are responsive to anti-VEGF therapy and are 50 years of age or older. The study is designed to evaluate four doses of RGX-314 (3 x 10^9 GC/eye, 1 x 10^10 GC/eye, 6 x 10^10 GC/eye, and 1.6 x 10^11 GC/eye). The primary purpose of the clinical study is to evaluate the safety and tolerability of RGX-314 at 24 weeks after a single dose administered by subretinal delivery. Primary endpoints include safety and tolerability and secondary endpoints include ocular examinations, visual acuity, imaging (including spectral domain optical coherence tomography (SD‑OCT)) and the need for additional anti-VEGF therapy. Following completion of the primary study period, subjects will enter a follow-up period and will continue to be assessed until week 106 for long-term safety and durability of effect.

About RGX-314
RGX-314 is being developed as a one-time subretinal treatment for wet AMD. It includes the NAV AAV8 vector encoding an antibody fragment which inhibits VEGF, modifying the pathway for formation of new leaky blood vessels which lead to retinal fluid accumulation and vision loss. In preclinical animal models with conditions similar to macular degeneration, significant and dose-dependent reduction of blood vessel growth and prevention of disease progression was observed after a single subretinal dose of RGX-314.

About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.